Why is Hims & Hers Health stock up 9.6% today?

Traders Union
All News
Stocks
Hims & hers surges 9.67% today

Highlights

Hims & Hers Health is scheduled to release third quarter 2026 earnings on November 9, with revenue expected at $892.88 million and earnings per share at $0.06.
Multiple securities class action lawsuits target the company, with an investor filing deadline set for November 2, 2026.
Shares of Hims & Hers Health trade below key short-term averages, momentum indicators remain negative, and the expected five-day price range is $25.36 to $30.70.

Investor flows intensify amid earnings expectations and legal pressures

Hims & Hers Health is seeing increased interest as it approaches its third quarter 2026 earnings release scheduled after market close on November 9, 2026, with revenue anticipated at $892.88 million and expected earnings per share of $0.06. The company is the subject of multiple securities class action lawsuits, with an investor filing deadline set for November 2, 2026. Legal challenges and upcoming earnings continue to focus market attention on the stock.

Anton Kharitonov, expert at Traders Union, sees Hims & Hers Health's recent surge as a fleeting technical bounce. He notes the stock remains below key averages, with momentum indicators and oscillators flashing persistent weakness. Legal issues and headline risk weigh heavily on market sentiment. Downside scenarios dominate near term price action, especially with resistance at $28.44 holding. "I see little room for upside while lawsuits and technical barriers persist — this setup favors patience and caution over chasing rebounds."

Viktoras Karapetjanc, expert at Traders Union, highlights growing interest as Hims & Hers Health approaches a pivotal earnings event. He sees these inflows and firm revenue expectations as signaling robust underlying demand. Karapetjanc believes the bullish structure remains intact if price consolidates above $26.97. "This market offers multiple setups, and I expect further growth once legal uncertainties clear and fundamental momentum persists."

Sholanke Dele, market strategist, remains cautious on Hims & Hers Health given headline risk from investor lawsuits and a volatile earnings outlook. He sees overall market sentiment as defensive, with sellers dominating short-term action. Dele warns the probability of a downward move is significant. "Given the legal overhang and weak intraday momentum, I advise staying defensive until price action improves."

Bearish momentum prevails as technical indicators signal oversold risk

Hims & Hers Health trades below its 20-day and 50-day moving averages ($28.53 and $28.76), while maintaining support above the 200-day moving average at $26.97. The nearest resistance is set at $28.44 (Ichimoku Kijun), with immediate support at $26.97. Momentum remains negative: the MACD and RSI indicate sell signals, with the RSI reading neutral at 39.28. Both the Stochastic RSI and Commodity Channel Index are in oversold zones, which suggests potential for an upside rebound. Bear/Bull Power (BBP) is negative, showing sellers dominate intraday, and the Awesome Oscillator also signals a bearish direction, highlighting overall momentum weakness.

Earlier, analysts noted that Hims & Hers Health faced persistent technical and legal headwinds that contributed to prevailing downside risks. The current analysis reinforces this outlook, with limited rebound potential ahead of earnings and a continued focus on the critical support level at $26.97 as the key downside inflection to monitor.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.